

Výsledná kategória (A–D) vychádza z kombinácie nálezu pri objektívnych vyšetreniach (pozitívne nálezy v pravom stĺpci) a subjektívnych symptómov (pozitívne nálezy v dolnom riadku). V prípade, že pacient trpí aj v dôsledku extrapulmonálnych symptómov, tak sa uvedie navyše písmeno „E“.

Významné patologické nálezy v rámci patologického hodnotenia:

LITERATÚRA

- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727-733.
- WHO1: [https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihf-emergency-committee-on-novel-coronavirus-\(2019-ncov\)](https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihf-emergency-committee-on-novel-coronavirus-(2019-ncov)) [Citované 17.5.2022].
- WHO2: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> [Citované 17.5.2022].
- WHO3: WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. <https://covid19.who.int/> [Citované 9.5.2022].
- Koronavírus na Slovensku v číslech – Koronavírus a Slovensko (gov.sk). <https://korona.gov.sk/koronavirus-na-slovensku-v-cisloch/> [Citované 9.5.2022].
- George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. *Lancet Respir Med* 2020;8:807-815. [https://doi.org/10.1016/S2213-2600\(20\)30225-3](https://doi.org/10.1016/S2213-2600(20)30225-3) [Citované 17.5.2022].
- Hall MW, Joshi I, Ooi EE. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. *Clin Infect Dis* 2022;74(1):144-148.
- Tanni SE, Fabro AT, de Albuquerque A, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. *Expert Rev Respir Med* 2021;15(6):791-803. <https://doi.org/10.1080/17476348.2021.1916472> [Citované 9.5.2022].
- Kumar N, Gupta A, Vardhan H et al. Post-COVID-19 Pulmonary Fibrosis: An Update. *J Adv Res Med* 2021;8(2):16-26.
- Ngai JC, Ko FW, Ng SS, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. *Respirology*. 2010;15(3):543-550. <https://doi.org/10.1111/j.1440-1843.2010.01720.x> [Citované 17.5.2022].
- Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian J Radiol Imaging*. 2017;27(3):342-349. https://doi.org/10.4103/ijri.IJRI_469_16 [Citované 17.5.2022].
- Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. *Bone Res* 2020;8:8.
- Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent Post-COVID-19 Interstitial Lung Disease An Observational Study of Corticosteroid Treatment. *Ann Am Thorac Soc* 2021;18(5):799-806. <https://doi.org/10.1513/AnnalsATS.202008-1002OC> [Citované 9.5.2022].
- Mo X, Jian W, Su Z, Chen M, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. *Eur Respir J* 2020;55(6):2001217.
- George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax* 2020;0:1-8. doi:10.1136/thoraxjnl-2020-215314 [Citované 9.5.2022].
- Sonnweber T, Sahanic S, Pizzini A, et al. Cardiopulmo-

- Funkčné vyšetrenie pľúc – difúzna kapacita pľúc (transfer faktor) – DLco < 80% náležitých hodnôt.
- 6-minútový test chôdze – 6MWT – či iná fyzická záťaž založená na chôdzi či jednoduchom pohybe vedie k poklesu saturácie kyslíka o > 4% alebo pri absolútnom poklese pod 90%.
- Patologické nálezy pri zobrazovacích vyšetreniach pľúc: RTG (skiagram) hrudníka

nary recovery after COVID-19: an observational prospective multicentre trial. *Eur Respir J* 2021;57:2003481. <https://doi.org/10.1183/13993003.03481-2020> [Citované 17.5.2022].

- Burnham EL, Hyzy RC, Paine R, et al. Chest CT features are associated with poorer quality of life in acute lung injury survivors. *Crit Care Med* 2013;41(2):445-456.
- Bazdyrev E, Rusina P, Panova M, et al. Lung Fibrosis after COVID-19: Treatment Prospects. *Pharmaceuticals* 2021;14:807. <https://doi.org/10.3390/ph14080807> [Citované 17.5.2022].
- Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. *Lung India* 2021;38:541-547.
- Rai DK, Sharma P, Kumar R. Post covid 19 pulmonary fibrosis- Is it reversible? *Indian Journal of Tuberculosis* 2021;3:330-333. <https://doi.org/10.1016/j.ijtb.2020.11.003> [Citované 9.5.2022].
- Arnold DT, Donald C, Lyon M, et al. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks. *PLOSone* 2021;16(4):e0249607. doi: 10.1371/journal.pone.0249607. eCollection 2021 [citované 17.5.2022].
- Huang W, Wu Z, Chen Z, et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. *J Infect* 2021;82:e5-e7. <https://doi.org/10.1016/j.jinf.2020.09.027> [Citované 17.5.2022].
- Laššán Š, Hájková M, Solovič I. Pozičný dokument a spoločné odporúčania hlavného odborníka Ministerstva zdravotníctva sr pre odbor pneumológie a ftizeológie a výboru Slovenskej pneumologickej a ftizeologickej spoločnosti SLS pre poskytovanie zdravotnej starostlivosti pacientom s pľúcnym postihnutím po prekonanom ochorení COVID-19. Dostupné na: https://spfs.sk/images/oznamy2021/post_covid_5-2021.pdf [Citované 17.5.2022].
- Kopecký M, Skála M, Neumannová K, et al. Poziční dokumenty České pneumologické a ftizeologické společnosti ČLS JEP - Post-COVID syndrom/postižení – definice, diagnostika a klasifikace. *pneumologie.cz* [online], 2021. <http://www.pneumologie.cz/upload/1624982759.pdf> [Citované 24.8.2022].
- Barouch NH. Covid-19 vaccines – immunity, variants, boosters. *N Engl J Med* 2022. DOI: 10.1056/NEJMra2206573 [Citované: 1.9.2022].
- Mohammed I, Nauman A, Paul P, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. *Human Vaccines Immunother* 2022;18(1):e2027160. <https://doi.org/10.1080/21645515.2022.2027160> [Citované: 1.9.2022].
- NIH. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <https://www.covid-19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/> [Citované: 11.8.2022].
- Laššán Š, Laššánová M. Stručný súhrn navrhovanej ambulancnej a ústavnej farmakologickej liečby ochorenia COVID-19 na Klinike pneumológie, ftizeológie a funkčnej diagnos-

(prípadne CT/HRCT pľúc, ultrasonografia pľúc a iné.) nevysvetliteľné inak. Medzi typické nálezy patria opacity charakteru mliečneho skla (periférne, bilaterálne), konsolidácie parenchýmu pľúc s voľným bronchogramom, zhrubnutie interlobulárnych sept, crazy paving, fibrózne pruhy a lineárne opacity, retikulácie, mierne zhrubnutie pleury a nevelké pleurálne výpotky.

tiky LF SZU a Univerzitetnej nemocnice Bratislava. *Respiro* 2021;19(4):24-67.

- Yu W, Guo F, Song X. Effects and Mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models. *Pharm Biol* 2017;55:450-455.
- Kostorz-Nosal S, Jastrzębski D, Chyra M, et al. A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia. *Eur Clin Respir J* 2021;8:1945186.
- Segala FV, Sgalla G, Salvati F, et al. Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure. *Respir Med* 2021;187:106571.
- Dhooira S, Chaudhary S, Sehgal IS, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). *Eur Respir J* 2022;59:2102930. DOI: 10.1183/13993003.02930-2021 [Citované 17.5.2022].
- Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: data from the whole IN-BUILD trial. *Eur Respir J* 2022;59:2004538. DOI: 10.1183/13993003.04538-2020 [Citované 17.5.2022].
- Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med* 2021;9:476-486. [https://doi.org/10.1016/S2213-2600\(20\)30554-3](https://doi.org/10.1016/S2213-2600(20)30554-3) [Citované 17.5.2022].
- Wollin L, Wex E, Pautsch A, et al. Mode of Action of Nintedanib in the treatment of idiopathic pulmonary fibrosis. *Eur Respir J* 2015;45:1434-1445.
- Margaritopoulos GA, Vasarmidi E, Antoniou KM. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: An evidence-based review of its place in therapy. *Core Evid* 2016;11:11-22.
- Wigén J, Löfdahl A, Bjermer L, et al. Converging pathways in pulmonary fibrosis and Covid-19 – The fibrotic link to disease severity. *Respir Med* 2020;2:100023. <https://doi.org/10.1016/j.jymex.2020.100023> [Citované 17.5.2022].
- <https://clinicaltrials.gov/ct2/results?cond=covid+19&term=pirfenidone&cntry=&state=&city=&dist=> [Citované 17.9.2022].
- Skala M, Svoboda M, Kopecký M, et al. Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia. *Virology* 2021;187:73. doi.org/10.1186/s12985-021-01546-8.
- Zhang C, Wu Z, Li JW, et al. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. *J Med Virol* 2021;93:1378-1386.
- Echeverría-Esnal D, Martín-Ontiyuelo C, Navarrete-Ruoco ME, et al. Azithromycin in the treatment of COVID-19: a review. *Expert Rev Antiinfective Ther* 2021;19(2):147-163. <https://doi.org/10.1080/14787210.2020.1813024> [Citované 17.5.2022].